帕罗西汀联合小剂量齐拉西酮治疗女性抑郁症的效果及安全性

发布时间：2019-05-14 09:02

【摘要】：目的探讨帕罗西汀联合小剂量齐拉西酮对女性抑郁症疗效及安全性评价。方法选取收治的110例女性抑郁患者,分为对照组和观察组,对照组使用帕罗西汀单独治疗,观察组使用帕罗西汀和小剂量齐拉西酮联合治疗,对比观察两组患者的临床疗效、汉密斯顿抑郁量表(HAMD)评分和不良反应。结果两组患者经8周治疗后,对照组患者总有效率为63.64%,观察组患者总有效率为83.64%,对照组总有效率明显低于观察组,差异有统计学意义(醊2=5.666 2,P0.05);治疗前对照组与观察组患者的HAMD评分值之间差异无统计学意义(P0.05);治疗2、4、6周后,观察组的HAMD评分值与对照组比较差异有统计学意义(P0.01),治疗8周后两组患者的HAMD评分值之间差异无统计学意义(P0.05)。对照组与观察组均无明显的不良反应产生。结论帕罗西汀联合齐拉西酮治疗抑郁症具有较好的临床疗效,治疗周期短,安全性高,无不良发应,值得临床推广。
[Abstract]:Objective to evaluate the efficacy and safety of paroxetine combined with low dose ziprasidone in the treatment of female depression. Methods 110 female patients with depression were divided into control group and observation group. The control group was treated with paroxetine alone, the observation group was treated with paroxetine and low dose ziprasidone, and the clinical efficacy of the two groups was compared. Hamilton depression scale (HAMD) score and adverse reactions. Results after 8 weeks of treatment, the total effective rate was 63.64% in the control group and 83.64% in the observation group. The total effective rate in the control group was significantly lower than that in the observation group (鈮，

本文编号：2476584